S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Price, News & Analysis

$3.75
+0.01 (+0.27%)
(As of 03/27/2024 ET)
Today's Range
$3.65
$3.89
50-Day Range
$3.28
$5.07
52-Week Range
$1.30
$5.22
Volume
2.63 million shs
Average Volume
2.53 million shs
Market Capitalization
$2.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Summit Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
113.3% Upside
$8.00 Price Target
Short Interest
Bearish
20.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.40mentions of Summit Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$487,500 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

679th out of 939 stocks

Pharmaceutical Preparations Industry

314th out of 431 stocks

SMMT stock logo

About Summit Therapeutics Stock (NASDAQ:SMMT)

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

SMMT Stock Price History

SMMT Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Summit Therapeutics plc (SMMT)
Q4 2023 Summit Therapeutics Inc Earnings Call
SMMT Mar 2024 4.000 put
SMMT Apr 2024 3.000 call
See More Headlines
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SMMT
Employees
105
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+113.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-614,930,000.00
Pretax Margin
-271,685.00%

Debt

Sales & Book Value

Annual Sales
$700,000.00
Book Value
$0.11 per share

Miscellaneous

Free Float
114,378,000
Market Cap
$2.63 billion
Optionable
Optionable
Beta
-1.21
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Robert W. DugganMr. Robert W. Duggan (Age 79)
    Co-CEO & Executive Chairman
  • Dr. Mahkam Zanganeh D.D.S. (Age 54)
    M.B.A., Co-CEO, President & Director
    Comp: $657.81k
  • Mr. Ankur  DhingraMr. Ankur Dhingra (Age 47)
    Chief Financial Officer
    Comp: $530k
  • Mr. Manmeet Singh Soni (Age 46)
    COO & Director
    Comp: $591.5k
  • Prof. Dame Kay Davies DBE (Age 73)
    FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Ms. Abby Guzman Murphy
    Head of Human Resources
  • Ms. Divya Chari (Age 56)
    Head of Global Clinical Operations
  • Mr. Dave Gancarz
    Chief Business & Strategy Officer?
  • Mr. Will Black
    Head of Information Technology?
  • Dr. Betty Y. Chang Ph.D.
    Head of Research, Oncology & Inflammation?

SMMT Stock Analysis - Frequently Asked Questions

Should I buy or sell Summit Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SMMT shares.
View SMMT analyst ratings
or view top-rated stocks.

What is Summit Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 1 year price objectives for Summit Therapeutics' stock. Their SMMT share price targets range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 113.3% from the stock's current price.
View analysts price targets for SMMT
or view top-rated stocks among Wall Street analysts.

How have SMMT shares performed in 2024?

Summit Therapeutics' stock was trading at $2.61 at the beginning of the year. Since then, SMMT stock has increased by 43.7% and is now trading at $3.75.
View the best growth stocks for 2024 here
.

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SMMT earnings forecast
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.05) earnings per share for the quarter. The company earned $0.20 million during the quarter.

What ETFs hold Summit Therapeutics' stock?

ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Summit Therapeutics own?
When did Summit Therapeutics IPO?

Summit Therapeutics (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.00%), Vanguard Group Inc. (1.00%), Northern Trust Corp (0.16%), Charles Schwab Investment Management Inc. (0.14%), Steward Partners Investment Advisory LLC (0.09%) and Nuveen Asset Management LLC (0.08%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SMMT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners